Simple Search Results

Query String: T-cell vaccination TCV

BDBM50611988 T-91825 T 91825 CEFTAROLINE
US9539260, T US9763952, Example T BDBM204130
t-2,4-PDC BDBM85211 t-PDC
US10125100, Example 17(t) US10941115, Example 17(t) US9751837, Example 17(t) BDBM298414 US10392346, Example 17(t)
BDBM448088 US11267820, Compound t US10689395, Compound t
J2.179.155E T-817ma BDBM50559172 T-817 maleate

Casarez, A; Kellar, T COMPOUNDS USEFUL AS T CELL ACTIVATORS US Patent US20230271954 (2023)
Chupak, LS; Ding, M; Gentles, RG; Huang, Y; Martin, SW; Mcdonald, IM; Mercer, SE; Olson, RE; Velaparthi, U; Wichroski, M; Zheng, X Naphthyridinone compounds useful as T cell activators US Patent US11866430 (2024)
Gentles, RG; Velaparthi, U; Ding, M; Olson, RE; Martin, SW; Roy, S; Jalagam, PR; Warrier, JS; Chupak, LS; Grunenfelder, DC Substituted bicyclic compounds useful as T cell activators US Patent US11964973 (2024)
Velaparthi, U; Olson, RE; Darne, CP; Dasgupta, B; Warrier, JS; Rahaman, H; Jalagam, PR; Roy, S; Grunenfelder, DC Substituted pyridopyrimidinonyl compounds useful as T cell activators US Patent US11584747 (2023)
KUGLER, DG; QIN, J; MAIER, A; OLSON, R; WICHROSKI, M; VELAPARTHI, U; DARNE, CP; DASGUPTA, B; GRUNENFELDER, DC; WARRIER, JS; RAHAMAN, H; JALAGAM, PR; ROY, S; SIVAKUMAR, P COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR US Patent US20240108654 (2024)
Tremblay, ML; Pike, K; Perez Quintero, LA Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP) US Patent US11597739 (2023)
Hudson, R; Beausoleil, A Compounds and methods for modulating interleukin-2-inducible t-cell kinase US Patent US11008314 (2021)
Wang, MS; Wang, ZZ; Li, ZL; Gong, Y; Duan, CX; Cheng, QH; Huang, W; Yang, GF Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy. J Med Chem 66: 611-626 (2023)
Selective Itk inhibitors block T-cell activation and murine lung inflammation.
Toutah, K; Nawar, N; Timonen, S; Sorger, H; Raouf, YS; Bukhari, S; von Jan, J; Ianevski, A; Gawel, JM; Olaoye, OO; Geletu, M; Abdeldayem, A; Israelian, J; Radu, TB; Sedighi, A; Bhatti, MN; Hassan, MM; Manaswiyoungkul, P; Shouksmith, AE; Neubauer, HA; de Araujo, ED; Aittokallio, T; Krämer, OH; Moriggl, R; Mustjoki, S; Herling, M; Gunning, PT Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. J Med Chem 64: 8486-8509 (2021)
PubChem, PC Dose Response of Developing T Cell Immune Modulators with powder sourced compounds PubChem Bioassay (2011)
Signaling function of PRC2 is essential for TCR-driven T cell responses.
Dai, XJ; Zhao, LJ; Yang, LH; Guo, T; Xue, LP; Ren, HM; Yin, ZL; Xiong, XP; Zhou, Y; Ji, SK; Liu, HM; Liu, HM; Liu, Y; Zheng, YC Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells. J Med Chem 66: 3896-3916 (2023)
Carpenter, RD; Andrei, M; Aina, OH; Lau, EY; Lightstone, FC; Liu, R; Lam, KS; Kurth, MJ Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin. J Med Chem 52: 14-9 (2009)
Winters, MP; Robinson, DJ; Khine, HH; Pullen, SS; Woska, JR; Raymond, EL; Sellati, R; Cywin, CL; Snow, RJ; Kashem, MA; Wolak, JP; King, J; Kaplita, PV; Liu, LH; Farrell, TM; DesJarlais, R; Roth, GP; Takahashi, H; Moriarty, KJ 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk). Bioorg Med Chem Lett 18: 5541-4 (2008)
Zhou, D; Zuo, Y; Pan, Z Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with J Med Chem 66: 4979-4998 (2023)
Zheng, S; Zhang, K; Zhang, X; Xiao, Y; Wang, T; Jiang, S Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. J Med Chem 65: 11900-11912 (2022)
Burgess, LE; Koch, K; Cooper, K; Biggers, MS; Ramchandani, M; Smitrovich, JH; Gilbert, EJ; Bruns, MJ; Mather, RJ; Donovan, CB; Hanson, DC The SAR of UK-78,282: A novel blocker of human T cell Kv1.3 potassium channels Bioorg Med Chem Lett 7: 1047-1052 (1997)
PubChem, PC Counterscreen for inhibitors of T-cell receptor (TCR)-CD3 interaction: Fluorescence-based biochemical high throughput dose response assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled BSA probe PubChem Bioassay (2013)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
Wang, Z; Zhang, M; Wang, J; Ji, H Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction. J Med Chem 62: 3617-3635 (2019)
Lentini, NA; Foust, BJ; Hsiao, CC; Wiemer, AJ; Wiemer, DF Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation. J Med Chem 61: 8658-8669 (2018)
Kadri, H; Taher, TE; Xu, Q; Sharif, M; Ashby, E; Bryan, RT; Willcox, BE; Mehellou, Y Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vγ9/Vδ2 T-Cell Immune Responses. J Med Chem 63: 11258-11270 (2020)
Asante-Appiah, E; Patel, S; Desponts, C; Taylor, JM; Lau, C; Dufresne, C; Therien, M; Friesen, R; Becker, JW; Leblanc, Y; Kennedy, BP; Scapin, G Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. J Biol Chem 281: 8010-5 (2006)
Pastor, RM; Burch, JD; Magnuson, S; Ortwine, DF; Chen, Y; De La Torre, K; Ding, X; Eigenbrot, C; Johnson, A; Liimatta, M; Liu, Y; Shia, S; Wang, X; Wu, LC; Pei, Z Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorg Med Chem Lett 24: 2448-52 (2014)
Cook, BN; Bentzien, J; White, A; Nemoto, PA; Wang, J; Man, CC; Soleymanzadeh, F; Khine, HH; Kashem, MA; Kugler, SZ; Wolak, JP; Roth, GP; De Lombaert, S; Pullen, SS; Takahashi, H Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design. Bioorg Med Chem Lett 19: 773-7 (2009)
Abraham, AD; Esquer, H; Zhou, Q; Tomlinson, N; Hamill, BD; Abbott, JM; Li, L; Pike, LA; Rinaldetti, S; Ramirez, DA; Lunghofer, PJ; Gomez, JD; Schaack, J; Nemkov, T; D'Alessandro, A; Hansen, KC; Gustafson, DL; Messersmith, WA; LaBarbera, DV Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem 62: 10182-10203 (2019)
Zhang, M; Catrow, JL; Ji, H High-Throughput Selectivity Assays for Small-Molecule Inhibitors of β-Catenin/T-Cell Factor Protein-Protein Interactions. ACS Med Chem Lett 4: 306-11 (2013)
Guo, J; Watson, A; Kempson, J; Carlsen, M; Barbosa, J; Stebbins, K; Lee, D; Dodd, J; Nadler, SG; McKinnon, M; Barrish, J; Pitts, WJ Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorg Med Chem Lett 19: 1935-8 (2009)
Ganapathy, ME; Prasad, PD; Huang, W; Seth, P; Leibach, FH; Ganapathy, V Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J Pharmacol Exp Ther 289: 251-60 (1999)
Burch, JD; Lau, K; Barker, JJ; Brookfield, F; Chen, Y; Chen, Y; Eigenbrot, C; Ellebrandt, C; Ismaili, MH; Johnson, A; Kordt, D; MacKinnon, CH; McEwan, PA; Ortwine, DF; Stein, DB; Wang, X; Winkler, D; Yuen, PW; Zhang, Y; Zarrin, AA; Pei, Z Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. J Med Chem 57: 5714-27 (2014)
Nguyen, C; Blanco, J; Mazaleyrat, JP; Krust, B; Callebaut, C; Jacotot, E; Hovanessian, AG; Wakselman, M Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26. J Med Chem 41: 2100-10 (1998)
MacKinnon, CH; Lau, K; Burch, JD; Chen, Y; Dines, J; Ding, X; Eigenbrot, C; Heifetz, A; Jaochico, A; Johnson, A; Kraemer, J; Kruger, S; Krülle, TM; Liimatta, M; Ly, J; Maghames, R; Montalbetti, CA; Ortwine, DF; Pérez-Fuertes, Y; Shia, S; Stein, DB; Trani, G; Vaidya, DG; Wang, X; Bromidge, SM; Wu, LC; Pei, Z Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK). Bioorg Med Chem Lett 23: 6331-5 (2013)
Qian, Z; Dougherty, PG; Liu, T; Oottikkal, S; Hogan, PG; Hadad, CM; Pei, D Structure-based optimization of a peptidyl inhibitor against calcineurin-nuclear factor of activated T cell (NFAT) interaction. J Med Chem 57: 7792-7 (2014)
Zapf, CW; Gerstenberger, BS; Xing, L; Limburg, DC; Anderson, DR; Caspers, N; Han, S; Aulabaugh, A; Kurumbail, R; Shakya, S; Li, X; Spaulding, V; Czerwinski, RM; Seth, N; Medley, QG Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay. J Med Chem 55: 10047-63 (2012)
Zhang, R INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE US Patent US20240139197 (2024)
Rabaaoui, S; Zouhiri, F; Lançon, A; Leh, H; d'Angelo, J; Wattel, E Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication. Antimicrob Agents Chemother 52: 3532-41 (2008)
Fournier, JF; Bhurruth-Alcor, Y; Musicki, B; Aubert, J; Aurelly, M; Bouix-Peter, C; Bouquet, K; Chantalat, L; Delorme, M; Drean, B; Duvert, G; Fleury-Bregeot, N; Gauthier, B; Grisendi, K; Harris, CS; Hennequin, LF; Isabet, T; Joly, F; Lafitte, G; Millois, C; Morgentin, R; Pascau, J; Piwnica, D; Rival, Y; Soulet, C; Thoreau, É; Tomas, L Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma. Bioorg Med Chem Lett 28: 2985-2992 (2018)
Lew, A; Chamberlin, AR Blockers of human T cell Kv1.3 potassium channels using de novo ligand design and solid-phase parallel combinatorial chemistry. Bioorg Med Chem Lett 9: 3267-72 (2000)
Sun, P; Wang, J; Khan, KS; Yang, W; Ng, BW; Ilment, N; Zessin, M; Bülbül, EF; Robaa, D; Erdmann, F; Schmidt, M; Romier, C; Schutkowski, M; Cheng, AS; Sippl, W Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties. J Med Chem 65: 16313-16337 (2022)
Khedkar, SA; Sun, X; Rigby, AC; Feinberg, MW Discovery of small molecule inhibitors to Krüppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiation. J Med Chem 58: 1466-78 (2015)
Rietz, TA; Teuscher, KB; Mills, JJ; Gogliotti, RD; Lepovitz, LT; Scaggs, WR; Yoshida, K; Luong, K; Lee, T; Fesik, SW Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). J Med Chem 64: 14757-14772 (2021)
Wang, T; Wang, K; Zhang, Y; Zhang, K; Cai, S; Jiang, S; Xiao, Y; Zhang, X Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA). J Med Chem 66: 11881-11892 (2023)
Chen, IJ; Chen, HL; Demetriou, M Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J Biol Chem 282: 35361-72 (2007)
Rebamipide and Derivatives are Potent, Selective Inhibitors of Histidine Phosphatase Activity of the Suppressor of T Cell Receptor Signaling Proteins.
Trani, G; Barker, JJ; Bromidge, SM; Brookfield, FA; Burch, JD; Chen, Y; Eigenbrot, C; Heifetz, A; Ismaili, MH; Johnson, A; Krülle, TM; MacKinnon, CH; Maghames, R; McEwan, PA; Montalbetti, CA; Ortwine, DF; Pérez-Fuertes, Y; Vaidya, DG; Wang, X; Zarrin, AA; Pei, Z Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK). Bioorg Med Chem Lett 24: 5818-23 (2014)
Tang, G; Liu, L; Wang, X; Pan, Z Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk). Eur J Med Chem 173: 167-183 (2019)